2025 annual financial data
Iovance Biotherapeutics 2025 Operating margin
Direct answer
Operating margin was -153.08%.
Operating income was -403,356,000 USD and net income was -390,978,000 USD.
Operating cash flow was -302,408,000 USD.
Get free Iovance Biotherapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 263,502,000 USD
- Operating income
- -403,356,000 USD
- Net income
- -390,978,000 USD
- Operating cash flow
- -302,408,000 USD